Eric Lefkofsky, Founder and CEO of Tempus AI, joins Dr. Sanjay Juneja and Dr. Doug Flora to explore how artificial intelligence, real-world data, genomic sequencing, and emerging technologies like organoids are reshaping oncology. From reducing diagnostic errors to matching patients with more effective therapies, AI is transforming how clinicians make decisions and how researchers develop the next generation of treatments. The conversation examines why healthcare adoption has lagged behind technological progress, the growing role of patient-driven intelligence, and how connected data may help eliminate thousands of preventable cancer deaths each year. Eric also shares his vision for AI-powered clinical decision support, digital twins, drug development, and the future relationship between physicians and intelligent systems.

The End of Trial-and-Error Cancer Care

AI and Healthcare

Welcome to AI and Healthcare. My name is Dr. Sanjay Janeja. I'm a hematologist and medical oncologist, also known as the OncDoc on news and social media. And I am joined by my co-host, Dr. Douglas Flora, who's a medical oncologist. He is the executive director of St. Elizabeth Healthcare and the chief editor of AI and Precision Oncology. And Doug, our guest today, you know, your exact words when I sought some advice from you, like I often do, was, that is a man that you want to spend any bit of time around if you can.

And the word you used was visionary. So if you could kind of tell our listeners, well, who do we have today and why you're excited? Well, thanks, Sanjay, for the handoff. And Eric, thank you for doing this. You are a personal hero of mine. So this is a fun day for me. We're going to have an insightful conversation. But for the audience who may not know you somehow, our guest founded Tempest AI, a company that, in my opinion, has arguably done more than any other single organization to turn cancer data from a liability into a weapon against cancer.

And Eric, like me, your story will get into, I'm sure, why you did this. And I've read it many times. I've heard you talk about your wife's experience and your experience where we were essentially flying blind. And so I credit you with doing something rather than nothing. And it's going to be important for our audience to understand where that passion has come from for you. Ten years later, now Tempest connects to nearly half of the U.S.

The End of Trial-and-Error Cancer Care

Read the full transcript

The candid version is on a podcast,
not the earnings call.

The End of Trial-and-Error Cancer Care

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.